{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-05-15T23:41:57.538Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   50-59   Skip unless catalyst <30d + insider cluster\n   < 50    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   < 60    Skip (no exception; small caps need a clear catalyst)\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"NTLA\",\n  \"company\": \"Intellia Therapeutics, Inc.\",\n  \"investigation_summary\": \"NTLA is a clinical-stage CRISPR gene editing company whose lead program lonvo-z (HAE) achieved positive Phase 3 HAELO data in April 2026 and initiated rolling BLA submission. The stock has already run from ~$8 lows to $13-14 on that news, now sitting roughly 52% below its 52-week high of $28.25. An FDA clinical hold on the ATTR program (nex-z) has been partially lifted with patient screening resumed as of May 2026 — a positive but unresolved risk remains in the background. No insider open-market purchases were found; CEO and CFO received RSU/option grants only, which are compensation events not directional conviction bets. The company is deeply loss-making (FCF burn ~$235M/year) with no product revenue. IV is elevated (~80%+ ATM). Given that the stock has already made its major Phase 3 run, analyst consensus target ($26.65) represents an optimistic scenario requiring BLA approval and commercial launch success — not a near-term base case. A range-bound income thesis (covered calls / strangles ahead of earnings and BLA catalysts) fits better than a directional long.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Intellia Therapeutics is a Cambridge, MA-based CRISPR gene editing company founded in 2014 with approximately 377 employees. The company's core platform leverages CRISPR/Cas9 technology delivered via lipid nanoparticles (LNPs) for in vivo genome editing and ex vivo engineered cell therapies. Its two lead programs are lonvoguran ziclumeran (lonvo-z, NTLA-2002) for hereditary angioedema (HAE), which reported positive Phase 3 HAELO data in April 2026 meeting all primary and secondary endpoints, and nexiguran ziclumeran (nex-z, NTLA-2001) for ATTR amyloidosis, which faced FDA clinical holds on both MAGNITUDE (ATTR-CM) and MAGNITUDE-2 (ATTRv-PN) trials but resumed patient screening in May 2026. Lonvo-z is the first in vivo CRISPR therapy to report positive Phase 3 data globally. The company has a collaboration with Regeneron Pharmaceuticals and owns significant platform IP around CRISPR/Cas9 delivery. Financial profile shows ~$66M TTM revenue (all from collaborations, no product sales), ~$376M cash and $382M in marketable securities, burning approximately $235M in free cash flow annually. Cash runway extends into 2028 post-$180M April equity raise.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": null\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-06\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026: EPS -$0.81 actual vs -$0.898 est (+11.6% beat). Prior four quarters also showed consistent positive beats of 2.5%, 7.8%, 13.7%. Revenue miss in Q1 (-3.12% surprise) but within acceptable range for a clinical-stage company.\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"HAELO Phase 3 topline data: lonvo-z met all primary and secondary endpoints in HAE, April 2026\",\n          \"date_or_window\": \"April 27-28, 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/ntla-falls-4-despite-strong-170200674.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"Rolling BLA submission initiated for lonvo-z in HAE; planned U.S. launch Q1 2027 if approved\",\n          \"date_or_window\": \"BLA: initiated April 2026; approval decision expected ~H2 2026 to support Q1 2027 launch\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-announces-first-quarter-113000709.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"FDA clinical hold partially lifted — patient screening resumed in MAGNITUDE and MAGNITUDE-2 trials for nex-z (ATTR). Prior hold reasons not publicly disclosed.\",\n          \"date_or_window\": \"May 2026 (8-K filed May 11, 2026)\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215721/ntla-20260511.htm\"\n          ],\n          \"directional_bias\": \"ambiguous\"\n        },\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 2026 earnings — August 6, 2026. BLA rolling submission ongoing; HAELO data full readout details likely presented.\",\n          \"date_or_window\": \"August 6, 2026\",\n          \"source_urls\": [],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": -7.23,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -3.73,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": -12.31,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"Traditional valuation metrics are irrelevant for a pre-product biotech with no earnings and heavy FCF burn. The stock has already re-rated significantly — from ~$8 lows in November 2025 to current $13.67 on Phase 3 success, representing a ~70% recovery from trough. Analyst consensus target of $26.65 (~95% upside) reflects the bull case assuming BLA approval and commercial launch by H1 2027. This is already partially priced in at current levels given the April run. At $13.67 vs. 52-week high of $28.25, stock trades roughly at midpoint — not obviously cheap nor richly valued for a binary-outcome biotech.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"B+\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 49,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 13.67,\n    \"ytd_return_pct\": 13.35,\n    \"from_52w_high_pct\": -51.6\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 filed Feb 26, 2026; large accelerated filer; cash $376M + marketable securities ~$450M; FCF burn ~$235M/year; no product revenue yet; clinical holds on MAGNITUDE/MAGNITUDE-2 for nex-z disclosed as top risk; HAELO Phase 3 topline expected mid-2026; Regeneron collaboration ongoing\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-11\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215740/ntla-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: revenue $15M (vs $16.6M YoY); R&D spend $80.7M vs $108.4M YoY (significant reduction reflecting program prioritization); operating loss ($100.5M) improved from ($120.8M) YoY; cash + marketable securities ~$517M total; 120.4M shares outstanding; ATM offerings raised $33.6M in Q1\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-05-11\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215721/ntla-20260511.htm\",\n      \"key_takeaways\": [\n        \"Q1 earnings release: HAELO topline positive April 27, rolling BLA initiated for lonvo-z; patient screening resumed in MAGNITUDE and MAGNITUDE-2 after FDA hold resolution; cash runway into 2028\"\n      ]\n    },\n    {\n      \"form\": \"10-Q (prior quarter)\",\n      \"filed\": \"2025-11-06\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312525269680/ntla-20250930.htm\",\n      \"key_takeaways\": [\n        \"Q3 2025: revenue $22M; R&D $96M; operating loss ($122.7M); showed prior quarters of consistent EPS beats\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-05-15\",\n      \"2026-06-18\",\n      \"2026-07-17\"\n    ],\n    \"iv_summary\": \"ATM IV at Jul 17 expiry (~62 DTE) is approximately 77-79% for near-ATM strikes. Put skew present — puts trade at a premium to equivalent calls, reflecting downside risk from binary trial/regulatory outcomes and overall biotech sector volatility.\",\n    \"notable_skew_or_flow\": \"Put/call ratio ~0.82 (net bull bias but weak). Notable new put positioning at $13 strike (V/OI=1.68) — 381 contracts traded vs 227 OI, suggesting hedging or new directional puts opened slightly OTM on the downside. Call OI concentrated at $14 (2,836), $16 (2,222) and $13 (1,411) strikes suggests covered call writing interest at current levels.\"\n  },\n  \"competitive_landscape\": \"CRISPR gene editing competitors include Vertex Pharmaceuticals/CRISPR Therapeutics (CTVT — already approved exa-cel for sickle cell/beta thalassemia), Beam Therapeutics (BEAM), Prime Medicine (PRME). For HAE specifically, KalVista was acquired by Chiesi in April 2026 ($1.9B deal), Takeda's Takhzyro (existing monoclonal antibody prophylaxis) is the current standard of care with ~$2B+ annual sales. Ionis has an ATTR amyloidosis siRNA program (eplontersen/Wainua). Alnylam also has ONPATTRO and Amvuttra for ATTR. NTLA's competitive differentiation is one-time CRISPR editing vs chronic therapies — if durable response confirmed, significant commercial potential.\",\n  \"key_risks\": [\n    \"FDA clinical hold on nex-z MAGNITUDE program partially resolved but underlying safety concerns not publicly disclosed; renewed dosing carries risk of additional regulatory action\",\n    \"Lonvo-z BLA approval required for commercialization; FDA may require additional data or longer follow-up from HAELO trial before approval\",\n    \"No product revenue and significant FCF burn (~$235M/year); requires ongoing capital raises causing dilution\",\n    \"Regeneron collaboration at risk if programs fail — Regeneron holds significant NTLA IP rights including right to sublicense certain technologies\",\n    \"CRISPR Therapeutics/Vertex already approved exa-cel in adjacent indication; potential for FDA scrutiny of safety profile unique to CRISPR delivery via LNPs\",\n    \"Short interest is ~39% of float, indicating significant bearish positioning that could create short-covering volatility\"\n  ],\n  \"what_the_market_might_be_missing\": \"The HAELO Phase 3 data announcement drove a sharp initial reaction but the stock subsequently sold off despite meeting all endpoints (the 'NTLA falls 4%' headline from April 28). The market may be under-appreciating the durability of lonvo-z's HAE benefit — if 12+ month follow-up data confirms single-infusion lifelong control, competitive positioning against chronic prophylaxis therapies like Takeda's Takhzyro becomes transformative. Additionally, the partial resolution of the FDA clinical hold on ATTR (nex-z) may not be fully reflected: screening resumed for both MAGNITUDE and MAGNITUDE-2 in May 2026, suggesting the agency accepted NTLA's response to its questions about the prior liver safety signal.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"going_concern\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"Q1 2026 10-Q / Earnings Release\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215740/ntla-20260331.htm\"\n    },\n    {\n      \"label\": \"8-K Q1 Results + Business Updates May 11, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215721/ntla-20260511.htm\"\n    },\n    {\n      \"label\": \"FY2025 10-K (Feb 26, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm\"\n    },\n    {\n      \"label\": \"CEO Form 4 — March 1, 2026 RSU grant\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088269/xslF345X05/ownership.xml\"\n    },\n    {\n      \"label\": \"CFO Form 4 — March 1, 2026 RSU grant\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088254/xslF345X05/ownership.xml\"\n    },\n    {\n      \"label\": \"NTLA Q1 Earnings Beat (Yahoo Finance)\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-inc-ntla-reports-124002615.html\"\n    },\n    {\n      \"label\": \"HAELO Phase 3 + BLA initiation news\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/ntla-falls-4-despite-strong-170200674.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-05-15T23:42:24.082Z",
      "raw_content": "<think>The dossier is for NTLA (Intellia Therapeutics).\nScout verdict: range_bound_or_income.\nStructure hints: cc, strangle, csp.\nAnti-signals present: dilution, going_concern.\nMarket cap: Not explicitly given, but cash is $376M + marketable securities ~$450M, shares outstanding 120.4M, price $13.67 -> Market cap ~$1.64B. So risk_class is \"asymmetric\" (≤ $5B).\nWait, the prompt says: \"ASYMMETRIC risk_class — strict sizing: < 60 Skip (no exception; small caps need a clear catalyst)\".\nAlso, anti-signal gates: \"Going-concern audit qualification\" and \"Customer concentration > 30%\" (not here), \"Convertible/warrant overhang creating dilution > 10% of float\" (dilution is listed as anti-signal).\nActually, the anti-signal says \"dilution\". The dossier mentions \"ATM offerings raised $33.6M in Q1\" and \"requires ongoing capital raises causing dilution\". Dilution > 10% of float? Shares outstanding 120M. ATM raised 33.6M -> ~28% dilution. That's a strong anti-signal.\nAlso \"going_concern\" is listed. The prompt says: \"Going-concern audit qualification\" is an anti-signal gate.\nGiven the anti-signals and the low score likely, I will skip.\n\nLet's score it anyway to be sure.\nA. Smart Money: 0 pts. (No insider buys, no 13F data fetched).\nB. Options Flow: IV elevated (~77-79%), put skew present. No whale call blocks. 0 pts.\nC. Catalyst: Earnings Aug 6 (within 90d), EPS surprise > 0% for last 4 quarters. 10 pts. BLA initiation (regulatory). Could add 8 pts? But cap is 25. Let's give 10 for earnings + positive surprise pattern.\nD. Mispricing: Forward PE negative, EV/EBITDA negative. 0 pts.\nE. Quality: ROIC null, gross margin null, net debt null. Balance sheet B+. 0 pts.\nF. Technical: Above 50DMA & 200DMA. 3 pts. RSI 49. 2 pts. Total 5 pts.\nTotal Score: ~15-20. Way below 60.\nAnti-signals: dilution, going_concern.\nVerdict: range_bound_or_income.\nStructure: Strangle or CC. But anti-signals and lack of catalyst/edge mean skip.\nReason: Heavy dilution risk and going-concern flags, combined with negative profitability and elevated IV, make this unsuitable for publication. The market is correctly pricing the binary execution risk and capital needs.\n\nI will output the skip JSON.\nCheck thresholds for asymmetric: < 60 Skip.\nScore breakdown: smart_money: 0, options_flow: 0, catalyst: 10, mispricing: 0, quality: 0, technical: 5. Total: 15.\nI'll adjust catalyst to 10 (earnings beat pattern). Technical to 5. Total 15.\nActually, I'll just give it a low score and skip.\nLet's construct the JSON carefully.\nRisk class: asymmetric.\nScore: 15.\nReason: \"Anti-signal gates (dilution and going-concern flags) and negative profitability metrics render this dossier unfit for publication. The market is correctly pricing the binary execution risk and capital needs, leaving no clear asymmetric edge or viable income structure.\"\nCheck structure: matches required schema.\nAll good.\nOutput matches exactly.\nProceed. \nWait, let's verify the anti-signal gate wording: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nThe dossier says dilution and going_concern are present. I will skip.\nScore breakdown: \nsmart_money: 0\noptions_flow: 0\ncatalyst: 10\nmispricing: 0\nquality: 0\ntechnical: 5\nTotal: 15.\nReady. \nOutput matches schema. No extra text.\nOne minor thing: The prompt says \"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object.\" but I am skipping, so I just output the skip JSON.\nDone. \nProceeding. \nOutput Generation. \n```json\n{\n  \"skip\": true,\n  \"score\": 15,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Anti-signal gates (dilution and going-concern flags) and negative profitability metrics render this dossier unfit for publication. The market is correctly pricing the binary execution risk and capital needs, leaving no clear asymmetric edge or viable income structure.\"\n}\n```\nDouble check the prompt: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will just skip. The score is low anyway.\nAll good. \nOutput matches exactly. \nProceeds. \n(Self-Correction/Refinement during thought)\nWait, the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will output raw JSON.\nCheck schema for skip:\n{\n  \"skip\": true,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": { ... },\n  \"reason\": \"...\"\n}\nMatches.\nDone. \nOutput Generation. \n[Done] \nProceeds. \n*(Self-Correction/Verification during generation prep)*\nI should make sure the JSON keys match exactly.\n\"skip\": true\n\"score\": 15\n\"score_breakdown\": { \"smart_money\": 0, \"options_flow\": 0, \"catalyst\": 10, \"mispricing\": 0, \"quality\": 0, \"technical\": 5 }\n\"reason\": \"...\"\nAll correct.\nOutput matches. \nProceeds. \n[Final Check of the Prompt]\n\"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object. Leave the others null/omitted.\" -> This applies to IF YOU PROCEED.\n\"IF YOU SKIP — output exactly: { ... }\"\nI will output exactly that.\nDone. \nOutput Generation. \n*(Done)*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 15,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Anti-signal gates (dilution and going-concern flags) and negative profitability metrics render this dossier unfit for publication. The market is correctly pricing the binary execution risk and capital needs, leaving no clear asymmetric edge or viable income structure.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 15,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Anti-signal gates (dilution and going-concern flags) and negative profitability metrics render this dossier unfit for publication. The market is correctly pricing the binary execution risk and capital needs, leaving no clear asymmetric edge or viable income structure.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 15,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 10,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 5\n  },\n  \"reason\": \"Anti-signal gates (dilution and going-concern flags) and negative profitability metrics render this dossier unfit for publication. The market is correctly pricing the binary execution risk and capital needs, leaving no clear asymmetric edge or viable income structure.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 26544,
  "stop_reason": "stop",
  "completed_at": "2026-05-15T23:42:24.082Z"
}